TY - JOUR
T1 - Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
AU - Cohorte de la Red de Investigación en Sida
AU - Alvarez, M.
AU - Monge, S.
AU - Chueca, N.
AU - Guillot, V.
AU - Viciana, P.
AU - Anta, L.
AU - Rodriguez, C.
AU - Gomez-Sirvent, J. L.
AU - Navarro, G.
AU - Santos, I. de los
AU - Moreno, S.
AU - García, F.
AU - del Amo, Julia
AU - Muñoz-Fernández, M. Ángeles
AU - Vegas, Paz Sobrino
AU - Sebastián, Victoria Hernando
AU - Ferreras, Belén Alejos
AU - Álvarez, Débora
AU - Jarrín, Inma
AU - Cachafeiro, Santiago Pérez
AU - García-Merino, Isabel
AU - Rico, Coral Gómez
AU - de la Fuente, Jorge Gallego
AU - Torre, Almudena García
AU - álvarez, Víctor Asensi
AU - Valle, Eulalia
AU - Cartón, José Antonio
AU - Melón, Santiago
AU - Fortúnez, Patricia Rodríguez
AU - Valls, María Remedios Alemán
AU - Socas, María del Mar Alonso
AU - Hernández, María Inmaculada Hernández
AU - Díaz-Flores, Felicitas
AU - Rosado, Dácil García
AU - González, Ricardo Pelazas
AU - Soriano, Vicente
AU - Labarga, Pablo
AU - Barreiro, Pablo
AU - Blanco, Francisco
AU - Carbonero, Luz Martín
AU - Vispo, Eugenia
AU - Solera, Carmen
AU - de Mendoza, Carmen
AU - Treviño, Ana
AU - Poveda, Eva
AU - Manuzza, Gustavo
AU - Miró, José M.
AU - Manzardo, Christian
AU - Zamora, Laura
AU - Ibáñez, Laura
N1 - Funding Information:
Financial support was received from Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativaen Sida [ ISCIII-RETIC RD06/006 ] and through Grant no. PI12/01053 cofunded by FEDER .
Publisher Copyright:
© 2014 European Society of Clinical Microbiology and Infectious Diseases.
PY - 2015
Y1 - 2015
N2 - We characterized transmitted drug resistance to rilpivirine and the predicted efficacy of first-line rilpivirine-containing regimens in antiretroviral-naive Spanish patients. International Antiviral Society-USA mutations were detected in 138 of 2781 patients (4.9%), E138A (3.4%) being the most prevalent. Using the Stanford Algorithm, 121 patients (4.4%) showed low-level or intermediate resistance. No differences in the predicted efficacy of first-line non-nucleoside reverse transcriptase inhibitor-based regimens were observed. As rilpivirine becomes more widely used in clinical practice, the evolution of its transmitted drug resistance will need to be monitored. In addition, the exact role of E138A singletons on rilpivirine activity as part of first-line regimens merits further evaluation.
AB - We characterized transmitted drug resistance to rilpivirine and the predicted efficacy of first-line rilpivirine-containing regimens in antiretroviral-naive Spanish patients. International Antiviral Society-USA mutations were detected in 138 of 2781 patients (4.9%), E138A (3.4%) being the most prevalent. Using the Stanford Algorithm, 121 patients (4.4%) showed low-level or intermediate resistance. No differences in the predicted efficacy of first-line non-nucleoside reverse transcriptase inhibitor-based regimens were observed. As rilpivirine becomes more widely used in clinical practice, the evolution of its transmitted drug resistance will need to be monitored. In addition, the exact role of E138A singletons on rilpivirine activity as part of first-line regimens merits further evaluation.
KW - Naive adults
KW - Resistance mutations
KW - Rilpivirine
KW - Therapeutic barrier
UR - http://www.scopus.com/inward/record.url?scp=84926287095&partnerID=8YFLogxK
U2 - 10.1016/j.cmi.2014.08.005
DO - 10.1016/j.cmi.2014.08.005
M3 - Article
C2 - 25636936
AN - SCOPUS:84926287095
SN - 1198-743X
VL - 21
SP - 104.e1-104.e5
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - 1
ER -